NYSE$AHR
American Healthcare REIT Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
American Healthcare REIT Inc announced third quarter 2024 results and updated its full year 2024 guidance.
American Healthcare REIT reported a GAAP net loss of $(3.1) million and Normalized Funds from Operations attributable to common stockholders (“NFFO”) of $0.36 per diluted share for the three months ended September 30, 2024. Achieved total portfolio Same-Store Net Operating Income (“NOI”) growth of 17.0% for the three months ended September 30, 2024 compared to the same period in 2023.
- Reported GAAP net loss of $(3.1) million and GAAP net loss attributable to common stockholders of $(0.03) per diluted share for the three months ended September 30, 2024.
- Reported Normalized Funds from Operations attributable to common stockholders (“NFFO”) of $0.36 per diluted share for the three months ended September 30, 2024.
- Achieved total portfolio Same-Store Net Operating Income (“NOI”) growth of 17.0% for the three months ended September 30, 2024 compared to the same period in 2023, highlighted by 61.8% and 22.6% Same-Store NOI growth from its senior housing operating properties (“SHOP”) and integrated senior health campuses (“ISHC”), respectively.
- The Company is increasing total portfolio Same-Store NOI growth guidance from a range of 12.0% to 14.0% to a revised range of 15.0% to 17.0%, for the year ending December 31, 2024.
Headline financials
Revenue & EPS history
American Healthcare REIT Inc · Revenue · Quarterly
$477M
Revenue by segment
American Healthcare REIT Inc · $543M total across 4 segments · Q4 2024
- ISHC$423M—78.0%
- SHOP$73.5M—13.6%
- Outpatient Medical$33.3M—6.1%
- Triple-Net Leased$12.6M—2.3%
Forward guidance
The Company’s guidance for the year ending December 31, 2024, is being increased to reflect the impact of the acquisition of the minority membership interest in Trilogy Holdings and management's improved outlook on portfolio performance.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 11 quarterly earnings reports · overlaid with Q3 2024
+1.8%
Avg return
Earnings day
+2.2%
Avg return
5 days after
+3.9%
Avg return
30 days after
64%
7 / 11 earnings
Positive
+8.3%
Q1 2025
Best reaction
-2.1%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.3% | +4.1% | -4.2% | |
| Q4 2025 | -2.1% | -2.5% | -11.4% | |
| Q3 2025 | +3.0% | -0.1% | +4.6% | |
| Q2 2025 | +1.3% | +2.0% | +7.2% | |
| Q1 2025 | +8.3% | +6.1% | +10.2% | |
| Q4 2024 | -1.3% | +0.7% | +0.8% | |
| Q3 2024 | +1.2% | +2.7% | +7.1% | |
| Q2 2024 | +3.3% | +3.6% | +35.1% | |
| Q1 2024 | -0.1% | +3.5% | +6.2% | |
| Q2 2023 | +2.8% | +1.3% | -6.8% | |
| Q4 2023 | -0.8% | +3.2% | -5.9% | |
| Q3 2023 | — | — | — | |
| Q1 2023 | — | — | — | |
| Q4 2022 | — | — | — | |
| Q3 2022 | — | — | — | |
| Q2 2022 | — | — | — | |
| Q1 2022 | — | — | — | |
| Q4 2021 | — | — | — | |
| Q3 2021 | — | — | — | |
| Q2 2021 | — | — | — | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro